according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formu**lation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 1842229-00015 Date of first issue: 19.07.2017 3.11

### 1. PRODUCT AND COMPANY IDENTIFICATION

Gentamicin / Betamethasone Ointment Formulation Product name

Manufacturer or supplier's details

: Organon & Co. Company

Address 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

### 2. HAZARDS IDENTIFICATION

### Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

#### Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

**GHS Classification** 

Reproductive toxicity : Category 1B

repeated exposure

Specific target organ toxicity - : Category 1 (Pituitary gland, Immune system, muscle, thymus

gland, Blood, Adrenal gland)

Short-term (acute) aquatic

hazard

Category 2

Long-term (chronic) aquatic

hazard

Category 1

**GHS** label elements

Hazard pictograms





Signal word Danger

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

Hazard statements : H360D May damage the unborn child.

H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through pro-

longed or repeated exposure. H401 Toxic to aquatic life.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P203 Obtain, read and follow all safety instructions before use. P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P318 IF exposed or concerned, get medical advice.

P391 Collect spillage.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

#### Other hazards which do not result in classification

None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

## Components

Chemical name	CAS-No.	Concentration (% w/w)
Petrolatum	8009-03-8	94.8
Paraffin oil	8012-95-1	5
Gentamicin	1403-66-3	0.1
betamethasone	378-44-9	0.064

### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version **Revision Date:** SDS Number: Date of last issue: 04.04.2023 30.09.2023 1842229-00015 Date of first issue: 19.07.2017 3.11

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

May damage the unborn child.

delayed Protection of first-aiders Causes damage to organs through prolonged or repeated exposure.

First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

#### 5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Hazardous combustion prod: :

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

Exposure to combustion products may be a hazard to health.

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Avoid release to the environment. **Environmental precautions** 

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for Sweep up or vacuum up spillage and collect in suitable con-

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

containment and cleaning up tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

### 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Petrolatum	8009-03-8	TWA (Mist)	5 mg/m3	IN OEL
		STEL (Mist)	10 mg/m3	IN OEL
		TWA (Inhal-	5 mg/m3	ACGIH
		able particu-		
		late matter)		
Paraffin oil	8012-95-1	TWA (Mist)	5 mg/m3	IN OEL
		STEL (Mist)	10 mg/m3	IN OEL
		TWA (Inhal-	5 mg/m3	ACGIH
		able particu- late matter)		
Gentamicin	1403-66-3	TWA	0.1 mg/m3 (OEB	Internal

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 1842229-00015 Date of first issue: 19.07.2017 3.11

			2)		
	Further information: OTO				
betamethasone	378-44-9	TWA	1 μg/m3 (OEB 4)	Internal	
	Further information: Skin				
		Wipe limit	10 μg/100 cm <sup>2</sup>	Internal	

**Engineering measures** Containment technologies suitable for controlling compounds

> are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from

stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

Personal protective equipment

If adequate local exhaust ventilation is not available or expo-Respiratory protection

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Combined particulates and organic vapour type

Filter type

Material

Hand protection

Chemical-resistant gloves

Remarks Consider double gloving.

Eye protection Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Work uniform or laboratory coat. Skin and body protection

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

If exposure to chemical is likely during typical use, provide eye Hygiene measures

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

Appearance : ointment

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not classified as a flammability hazard

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

: No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 30.09.2023 1842229-00015 Date of first issue: 19.07.2017 3.11

Molecular weight : No data available

Particle size No data available

## 10. STABILITY AND REACTIVITY

Not classified as a reactivity hazard. Reactivity Stable under normal conditions. Chemical stability Can react with strong oxidizing agents.

Possibility of hazardous reac- :

tions

None known. Conditions to avoid Incompatible materials Oxidizing agents

Hazardous decomposition

products

No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Information on likely routes of: Skin contact

exposure Ingestion

Eye contact

### **Acute toxicity**

Not classified based on available information.

## **Components:**

Petrolatum:

Acute oral toxicity LD50 (Rat): > 5,000 mg/kg

Method: OECD Test Guideline 401

Remarks: Based on data from similar materials

Acute dermal toxicity LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Remarks: Based on data from similar materials

Paraffin oil:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Rabbit): > 2,000 mg/kg Acute dermal toxicity

Assessment: The substance or mixture has no acute dermal

toxicity

Gentamicin:

LD50 (Rat): 8,000 - 10,000 mg/kg Acute oral toxicity

LD50 (Mouse): 10,000 mg/kg

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of :

administration)

LD50 (Rat): 67 - 96 mg/kg Application Route: Intravenous

Application Route. Intraverious

LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg Application Route: Intravenous

betamethasone:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l

Exposure time: 4 h

## Skin corrosion/irritation

Not classified based on available information.

### **Components:**

Petrolatum:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Paraffin oil:

Species : Rabbit

Result : No skin irritation

Gentamicin:

Species : Rabbit

Result : Mild skin irritation

betamethasone:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

**Components:** 

Petrolatum:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Remarks : Based on data from similar materials

Paraffin oil:

Species : Rabbit

Result : No eye irritation

Gentamicin:

Species : Rabbit

Result : Mild eye irritation

betamethasone:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

**Components:** 

Petrolatum:

Test Type : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

Gentamicin:

Remarks : No data available

betamethasone:

Exposure routes : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity

Not classified based on available information.

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

**Components:** 

Petrolatum:

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intraperitoneal injection Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Gentamicin:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Intravenous injection

Result: negative

betamethasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Application Route: Oral Result: equivocal

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

**Components:** 

Petrolatum:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years
Result : negative

**Gentamicin:** 

Carcinogenicity - Assess-

ment

No data available

Reproductive toxicity

May damage the unborn child.

**Components:** 

Petrolatum:

Effects on fertility : Test Type: Reproduction/Developmental toxicity screening

test

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Skin contact

Result: negative

Remarks: Based on data from similar materials

Gentamicin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Fertility: NOAEL: 20 mg/kg body weight

Result: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

Developmental Toxicity: NOAEL: 3.6 mg/kg body weight

Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 75 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 10 mg/kg body weight

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intraperitoneal

Developmental Toxicity: LOAEL: 50 mg/kg body weight Result: foetal mortality, No malformations were observed.

Reproductive toxicity - As-

sessment

Positive evidence of adverse effects on development from

human epidemiological studies.

betamethasone:

Effects on foetal develop-

ment

Species: Rabbit

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 0.05 mg/kg body weight Result: Fetotoxicity, Malformations were observed.

Species: Rat

Application Route: Subcutaneous

Developmental Toxicity: LOAEL: 0.42 mg/kg body weight

Result: Malformations were observed.

Species: Mouse

Application Route: Intramuscular

Developmental Toxicity: LOAEL: 1 mg/kg body weight

Result: Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

### STOT - single exposure

Not classified based on available information.

## STOT - repeated exposure

Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

### Components:

Gentamicin:

Target Organs : Kidney, inner ear

Assessment : Causes damage to organs through prolonged or repeated

exposure.

betamethasone:

Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood,

Adrenal gland

Assessment : Causes damage to organs through prolonged or repeated

exposure.

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

## Repeated dose toxicity

### **Components:**

### Petrolatum:

Species : Rat

NOAEL : 5,000 mg/kg
Application Route : Ingestion
Exposure time : 2 yr

#### Paraffin oil:

Species : Rat, female LOAEL : 161 mg/kg Application Route : Ingestion Exposure time : 90 Days

#### Gentamicin:

Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney

Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks

Target Organs : Kidney, inner ear

Species : Monkey
LOAEL : 6 mg/kg
Application Route : Intramuscular
Exposure time : 3 Weeks

Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 10 mg/kg

Application Route : Intramuscular

Exposure time : 52 Weeks

Target Organs : Kidney, Blood

Species : Rat

NOAEL : 12.5 mg/kg
LOAEL : 50 mg/kg
Application Route : Intramuscular
Exposure time : 13 Weeks
Target Organs : Kidney

## betamethasone:

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

Species : Rabbit
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 10 - 30 d

Target Organs : Pituitary gland, Immune system, muscle

Species : Rat
LOAEL : 0.05 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Mouse
LOAEL : 0.1 %
Application Route : Skin contact
Exposure time : 8 Weeks
Target Organs : thymus gland

Species : Dog

LOAEL : 0.05 mg/kg

Application Route : Oral Exposure time : 28 d

Target Organs : Blood, thymus gland, Adrenal gland

## **Aspiration toxicity**

Not classified based on available information.

### Components:

#### Paraffin oil:

The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

## **Experience with human exposure**

## **Components:**

### Gentamicin:

Ingestion : Target Organs: Kidney

Target Organs: inner ear

Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal

deafness

betamethasone:

Inhalation : Target Organs: Adrenal gland

Skin contact : Symptoms: Redness, pruritis, Irritation

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

### 12. ECOLOGICAL INFORMATION

### **Ecotoxicity**

## **Components:**

Petrolatum:

Toxicity to fish : LL50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 203

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10,000 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

NOEL (Pseudokirchneriella subcapitata (green algae)): >=

100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction

Method: OECD Test Guideline 201

Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 10 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Paraffin oil:

Toxicity to fish : LL50 (Scophthalmus maximus (turbot)): > 100 mg/l

Exposure time: 96 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to daphnia and other :

aquatic invertebrates

EL50 (Acartia tonsa (Calanoid copepod)): > 100 mg/l

Exposure time: 48 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

Toxicity to algae/aquatic

plants

EL50 (Skeletonema costatum (marine diatom)): > 100 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

NOELR (Skeletonema costatum (marine diatom)): > 1 mg/l

Exposure time: 72 h

Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

Gentamicin:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 86 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 10

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5

μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to microorganisms

EC50: 288.7 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

M-Factor (Chronic aquatic

toxicity)

: 1

betamethasone:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): > 50 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 ( Pseudokirchneriella subcapitata (green algae)): > 34

mg/l Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34

mg/l

according to the Globally Harmonized System



# **Gentamicin / Betamethasone Ointment Formulation**

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.052 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

NOEC: 0.07 µg/l Exposure time: 219 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 229

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 8 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

1,000

### Persistence and degradability

## Components:

Petrolatum:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 31 % Exposure time: 28 d

Method: OECD Test Guideline 301F

Remarks: Based on data from similar materials

Gentamicin:

Biodegradability : Result: rapidly degradable

Biodegradation: 100 % Exposure time: 28 d

Method: OECD Test Guideline 314

## **Bioaccumulative potential**

### Components:

Paraffin oil:

Partition coefficient: n- : log Pow: > 4

octanol/water Remarks: Calculation

Gentamicin:

Partition coefficient: n-

octanol/water

log Pow: < -2

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.11 30.09.2023 1842229-00015 Date of first issue: 19.07.2017

betamethasone:

Partition coefficient: n-

octanol/water

log Pow: 2.11

Mobility in soil

No data available

Other adverse effects

No data available

### 13. DISPOSAL CONSIDERATIONS

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

## 14. TRANSPORT INFORMATION

## International Regulations

**UNRTDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone, Gentamicin)

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(betamethasone, Gentamicin)

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo

aircraft)

Packing instruction (passen-

956

956

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(betamethasone, Gentamicin)

Class : 9

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

Packing group : III
Labels : 9
EmS Code : F-A

EmS Code : F-A, S-F Marine pollutant : yes

## Transport in bulk according to IMO instruments

Not applicable for product as supplied.

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### **16. OTHER INFORMATION**

Revision Date : 30.09.2023

**Further information** 

Sources of key data used to

compile the Safety Data Sheet

Data farmed

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

IN OEL : India. Permissible levels of certain chemical substances in

cy, http://echa.europa.eu/

: Internal technical data, data from raw material SDSs, OECD

eChem Portal search results and European Chemicals Agen-

work environment.

ACGIH / TWA : 8-hour, time-weighted average

IN OEL / TWA : Time-Weighted Average Concentration (TWA) (8 hrs.)

IN OEL / STEL : Short-term exposure Limit STEL (15 min)

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with

according to the Globally Harmonized System



# Gentamicin / Betamethasone Ointment Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.11
 30.09.2023
 1842229-00015
 Date of first issue: 19.07.2017

x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration: NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN